Document is current
Any future updates will be listed below
-
Authors
Zhang, Wen
Emanuel, Elizabeth R.
Yano, Hiroshi https://orcid.org/0000-0002-3098-2629
Uddin, Jazib https://orcid.org/0000-0001-5303-5213
Gaudino, Stephen
Xie, Zili https://orcid.org/0000-0002-9060-6780
Ichise, Hiroshi https://orcid.org/0000-0002-5187-810X
Wang, Zhen
Cowan, Maureen N. https://orcid.org/0000-0001-6842-8175
Lyu, Mengze https://orcid.org/0000-0002-8509-7969
Hou, Xiaoxiao https://orcid.org/0009-0005-6361-4047
Zeng, Peng
Hu, Elin https://orcid.org/0009-0001-9444-415X
Ribeiro de Godoy, Victoria
Grier, Alex
Estep, Nina https://orcid.org/0009-0000-3005-8885
Ishibashi, Julien R. https://orcid.org/0000-0002-7273-8034
Anover-Sombke, Stephanie https://orcid.org/0000-0002-8530-8068
Skene, Peter J. https://orcid.org/0000-0001-8965-5326
Mayassi, Toufic
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
Germain, Ronald N. https://orcid.org/0000-0003-1495-9143
Globig, Anna-Maria https://orcid.org/0000-0002-5236-7459
Heeg, Maximilian https://orcid.org/0000-0002-9594-1377
Goldrath, Ananda W.
Kim, Brian S. https://orcid.org/0000-0002-8100-7161
Hu, Hongzhen
Artis, David https://orcid.org/0000-0002-1753-4100
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 14 November 2025
First Online: 7 January 2026
Competing interests
: D.A. has contributed to scientific advisory boards at Boehringer-Ingelheim, Pfizer, Takeda and the Kenneth Rainin Foundation. B.S.K. is a founder of Alys Pharmaceuticals; he has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Attovia Therapeutics, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, Genentech, GlaxoSmithKline, LEO Pharma, Novartis, Pfizer, Recens Medical, Regeneron Pharmaceuticals, Sanofi, Septerna, Triveni Bio, and Vial; he has stock in ABRAX Japan, Alys Pharmaceuticals, Attovia Therapeutics, Locus Biosciences, Recens Medical, and Triveni Bio; and he holds a patent for the use of JAK1 inhibitors for chronic pruritus. The remaining authors declare no competing interests.
